|
|
Takeda Ventures, Inc. (TVI) is the corporate venture arm of Takeda Pharmaceutical Company Limited (TPC), a pharmaceutical company and the largest in Japan. TVI assumes the role of Takeda's former venture investment group, Takeda Research Investment, Inc., and remains a wholly owned subsidiary of Takeda America Holdings, Inc. The new group continues to seek strategic opportunities to complement and extend internal discovery capabilities, but will additionally explore potentially new business avenues for Takeda through external strategic venture activities. Takeda's strategic investment mandate means that while it will consider product, target and technology opportunities at any stage, the firm's focus is on start-up/seed rounds, through mid-stage financings. TVI intends to maintain a diverse investment portfolio, but is presently concentrating on drugs and biotherapeutics to treat cancer, metabolic disorders (obesity, diabetes, and dyslipidemias), cardiovascular disorders, chronic inflammatory disorders (particularly for gastrointestinal and bone and joint diseases) and diseases for the central nervous system (specifically Alzheimers Disease and schizophrenia). Additional areas of strategic importance are regenerative medicines, RNA and DNA modulation, novel vaccines technologies and innovative protein and peptide biotherapeutics. Currently, TVI does not invest in anti-infective diseases, medical devices, or diagnostics platforms.
|
